RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer

NCT05540483 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Biliary Carcinoma

Interventions

DRUG: Disitamab Vedotin combined with Zimberelizumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University